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Purpose: To report a case of retinal vasculitis associated with birdshot chorioretinitis which was
responsive to topical diﬂuprednate alone.
Observations: Two months after initiation of topical diﬂuprednate, ﬂuorescein angiography demon-
strated resolution of retinal vasculitis in both treated eyes. Worsening of vasculitis with attempted taper
of diﬂuprednate and subsequent control with prior dosing conﬁrmed the response.
Conclusions and importance: Despite potential adverse effects of steroid-induced glaucoma and cataract
formation, topical diﬂuprednate in the treatment of retinal vasculitis and other posterior uveitides may
have efﬁcacy.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Topical diﬂuprednate 0.05% is a potent steroid commonly used
for the treatment of anterior uveitis. For sight-threatening posterior
uveitis, topical steroid therapy is typically considered inadequate
and systemic therapy is indicated. There are reports of using topical
diﬂuprednate to treat pars planitis and Harada's disease but none
describing its use in birdshot chorioretinitis (BCR) [1,2]. Here, we
report successful treatment of retinal vasculitis associatedwith BCR
with topical diﬂuprednate alone.2. Case report
A 59-year old male with a history of HLA-A29 positive BCR
diagnosed nine years prior presented for follow-up to the uveitis
clinic at the Wilmer Eye Institute. He had been successfully treated
with mycophenolate mofetil for two years but stopped the medi-
cation in preparation for cardiac bypass surgery six months prior to
his clinic visit. After surgery, he had remained off all immunosup-
pression. He also had a history of mixed-mechanism glaucoma for
which he had undergone trabeculectomy OS (oculus sinister, leftlthcare System, Jamaica Plain
, MA 02130, USA
er).
access article under the CC BY-NCeye). He was maintained on brimonidine 0.2%-timolol 0.5% BID OD
(oculus dexter, right eye).
His visual acuities (VA) measured 20/20 OD and 20/15 OS. His
intraocular pressures (IOP) were 13 mmHg OD and 12 mmHg OS.
Slit lamp exam revealed trace anterior chamber (AC) cell OD and
1 þ AC cell OS with trace vitreous cells and no haze OU (oculus
uterque, both eyes). Dilated fundus exam revealed inactive
appearing birdshot lesions and absence of cystoid macular edema
or perivascular sheathing. The patient commenced topical diﬂu-
prednate QID OS and continued loteprednol 0.5% BID OD.
Six weeks later, the patient's visual acuity was 20/20 OU, and his
IOP was stable at 10mmHg OD and 14mmHg OS. He had controlled
AC inﬂammation OU but 1 þ vitreous cell without haze OD only.
The dilated fundus exam appeared stable compared to prior;
however, ﬂuorescein angiogram (FA) was obtained to assess for
occult vasculitis. The FA showed diffuse perivascular leakage
consistent with retinal vasculitis OD (Fig. 1A). There was no
angiographic evidence of vasculitis OS (Fig. 1B). Given the absence
of vasculitis OS on topical diﬂuprednate, we changed loteprednol to
diﬂuprednate QID OD and continued the same OS. We noted that a
differential effect of topical diﬂuprednate on retinal vasculitis may
be expected, as he was pseudophakic status post laser capsulotomy
OS and still had an early cataract OD.
Twomonths later, the patient's VA remained stable at 20/20 OU.
FA demonstrated resolution of the retinal vasculitis OD (Fig. 1C) and
no evidence of vasculitis OS (Fig. 1D). IOP, however, was 28 mmHg-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Initial late phase ﬂuorescein angiography photographs. Late phase ﬂuorescein angiography photographs showing evidence of perivascular leakage OD before treatment with
topical diﬂuprednate (A), and resolution after two months of treatment on QID dosing (C). Corresponding late phase angiography photographs show no evidence of perivascular
leakage OS (B, D) during continued therapy with topical diﬂuprednate.
Fig. 2. Follow up late phase ﬂuorescein angiography photographs and optical coherence tomography. Late phase ﬂuorescein angiography photographs showing evidence of mild
recurrence of perivascular leakage OD with tapering of topical diﬂuprednate to daily (A), and resolution on subsequent BID dosing (B). Optical coherence tomography of the maculae
of both eyes showing healthy ellipsoid zones and foveal contour, and no evidence of atrophy or cystoid macular edema OD (C) and OS (D).
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diﬂuprednate was tapered gradually to daily OD and BID OS.
At the next visit six weeks later, the patient's VA remained at 20/
20 OU, and IOPs were 15 mmHg OD and 14 mmHg OS. However, a
mild recurrence of retinal vasculitis in the right eye only was noted
on FA (Fig. 2A). The diﬂuprednate was increased back to BID OD,
and IOP lowering medication continued.
Three months later, having now received diﬂuprednate mono-
therapy for six months OD and nine months OS, the patient's VA
remained stable at 20/20 OU, and FA once again demonstrated no
evidence of retinal vasculitis (Fig. 2B). IOP was 26mmHg OD and 12
mmHg OS. Adequate control of his IOP was achieved with the
addition of dorzolamide BID OD and oral acetazolamide 250 mg
BID. Optical coherence tomography was obtained at this visit,
which demonstrated healthy ellipsoid zones and the absence of
atrophy or cystoid macular edema in both eyes (Fig. 2C,D).
3. Discussion
BCR is an uncommon, idiopathic posterior uveitis, for which
standard therapy consists of systemic steroids, steroid-sparing
immunosuppression including antimetabolites, T-cell inhibitors,
and biologic response modiﬁers, and occasionally the use of
intravitreal steroid injections and/or implants. Our case demon-
strates resolution of retinal vasculitis associated with BCR with
topical diﬂuprednate alone. Our patient had a history of mixed-
mechanism glaucoma and did develop steroid-induced ocular hy-
pertension, but this was managed by tapering the diﬂuprednate
and initiating additional IOP-lowering medication. Notably, recur-
rence of retinal vasculitis was observed OD with tapering to daily
dosing of topical diﬂuprednate but resolved with resumption of BID
dosing, providing additional evidence of a real treatment effect.
According to a recent report, topical diﬂuprednate resolved the
serous retinal detachments of three patients with Harada's disease
[2]. In each case, hourly dosing was initiated with a variable
tapering regimen based on clinical response. A mild steroid
response was observed in two out of three patients, which was
managed with topical IOP-lowering therapy. In addition, others
have previously demonstrated efﬁcacy in treating retinal edema
from other causes such as pseudophakic cystoid macular edema
and diabetic macular edema with topical diﬂuprednate [3,4]. In a
separate case report, twice a day dosing of topical diﬂuprednate
was adequate to treat pars planitis in a child for one year [1]. Thechild subsequently developed an atypical delayed steroid response
with ocular hypertension that was refractory to medical manage-
ment and rapid formation of a posterior subcapsular cataract,
which necessitated cessation of the steroid.
Diﬂuprednate is a prodrug that is converted to its active
metabolite diﬂuoroprednisolone butyrate by deacetylation after
penetration of the corneal epithelium [5]. It is a potent topical
corticosteroid owing to its high afﬁnity for glucocorticoid receptors.
Furthermore, its preparation as an emulsion may enhance ab-
sorption by the cornea [5]. In rabbits, topically applied diﬂupred-
nate rapidly distributes throughout all ocular tissues, including the
retina and choroid, with negligible systemic absorption [5], sug-
gesting that complications and adverse events associated with
systemic steroid and steroid-sparing immunosuppression may be
obviated.
4. Conclusions
Despite potential adverse effects of steroid-induced glaucoma
and cataract formation, our report suggests that topical diﬂupred-
nate in the treatment of retinal vasculitis and other posterior
uveitides may be considered as an adjunct or alternative to con-
ventional immunosuppression, especially when standard therapy
is contraindicated or poorly tolerated. We wish to underscore,
however, that close IOP monitoring is imperative for any patient
maintained on chronic diﬂuprednate.
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